Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs
- 1 February 1997
- journal article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 321 (2) , 225-230
- https://doi.org/10.1016/s0014-2999(96)00940-5
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Aquaretic effects of the nonpeptide V2 antagonist OPC-31260 in hydropenic humansKidney International, 1995
- Effects of Vasopressin V1 and V2 Receptor Antagonists on Progressive Renal Failure in RatsClinical Science, 1994
- Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men.Journal of Clinical Investigation, 1993
- Identification of functional oxytocin receptors in lactating rat mammary gland in vitroEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized ratAmerican Journal of Physiology-Renal Physiology, 1990
- Vascular vasopressin receptorsGeneral Pharmacology: The Vascular System, 1988
- Pharmacological characterization of vasopressin aggregation response of human plateletsThrombosis Research, 1985
- Characterization of human platelet vasopressin receptors.Journal of Clinical Investigation, 1985
- Hormonal Stimulation of Phosphatidylinositol Breakdown, with Particular Reference to the Hepatic Effects of VasopressinBiochemical Society Transactions, 1979
- Norepinephrine, vasopressin, glucagon, and A23187 induce efflux of calcium from an exchangeable pool in isolated rat hepatocytesProceedings of the National Academy of Sciences, 1978